It’s been a great year for stocks with fat profit margins.
Five fat-margin stocks that I recommended on Sept. 7, 2020 have returned 78.6% through Sept. 3 of this year.
Gamco Investors Inc. (GBL, Financial), Mario Gabelli (Trades, Portfolio)’s investment company, led the way with a 136% return. A year ago, I wrote that “I consider Mario Gabelli (Trades, Portfolio) a near-egomaniac…but then, so are many of the great practitioners of any art.” I recommended Gamco shares as “dirt cheap.”
Next best was Applied Materials Inc. (AMAT, Financial) with a 125% return, followed by Blackrock Inc. (BLK, Financial) at 69% and Cisco Systems Inc. (CSCO, Financial) at 50%. The laggard was Electronic Arts Inc. (EA, Financial), up 13%. For comparison, the Standard & Poor’s 500 Index returned 34% including dividends.
Today I’ll again offer you some recommendations on stocks with fat margins. Will they do as well as last year? Almost certainly not. Returns like that just don’t come along that often. I’ll be pleased if this year’s picks beat the S&P 500 by a few points.
I’ve written 11 columns on stocks with fat profit margins, and the average return has been 21.1%, versus 17.3% for the index. Eight of the 11 sets of recommendations have been profitable, but only three have beaten the S&P 500.
Bear in mind that my column results are hypothetical: They don’t reflect actual trades, trading costs or taxes. These results shouldn’t be confused with the performance of portfolios I manage for clients. Also, past performance doesn’t predict future results.
Now let’s take another swing. Here are five stocks I like that have unusually high profit margins (profits as a percent of sales).
Regeneron Pharmaceuticals Inc. (REGN, Financial), a biotech company based in Tarrytown, New York, makes the cocktail of antibodies used to treat former President Trump for Covid-19. I also makes Eylea, a drug used to treat age-related macular degeneration, a leading cause of blindness in old people.
In addition, Regeneron has several other approved drugs, and more in the pipeline. Its after-tax profit margin for the past four quarters is 50%, and it has been above 20% since 2017. The stock sells for 12 times recent earnings, and 15 times the earnings analysts predict for the next four quarters.
T. Rowe Price
T. Rowe Price Group Inc. (TROW, Financial), a mutual fund company with headquarters in Baltimore, boasts an after-tax margin of 42%. That margin has been 23% or better in each of the past 15 years. Over the past decade, it has grown its revenue at an 11% annual clip and earnings at 14%.
T. Rowe Price offers some index funds, but is best known for actively managed funds. It is particularly strong in corporate 401k plans. I’m a passionate believer in active management as opposed to index tracking.
A medical testing company based in San Diego, Quidel Corp. (QDEL, Financial) has posted a net margin of 49% lately. It sells for only seven times earnings because it gets much of its revenue from Covid-19 tests, and investors anticipate the end of the Covid pandemic.
I wish it were so, but I’m afraid that this nightmare will persist for quite a few more months. Even after Covid is tamed, I think we will be living in a world where medical tests are more frequent than they used to be.
One risk here is that car sales may slow due to the shortage of semiconductors used in them. But over the past 10 years, Gentex has grown its revenue at close to 10% a year, and earnings at better than 13%. That gives me some confidence.
For my final selection, I choose PotlatchDeltic Corp. (PCH, Financial), a real estate investment trust based in Spokane, Washington. It owns and manages forest land in Minnesota and four Southern states.
Lumber has been in keen demand lately, as housing has boomed. For PotlatchDeltic, last year was a great year compared to normal. But normal isn’t so bad: The company has shown a profit in 26 of the past 30 years (the loss years were 2000 to 2003). The recent net margin was 34%.
The stock sells for a modest seven times earnings.
John Dorfman is chairman of Dorfman Value Investments LLC in Boston, Massachusetts, and a syndicated columnist. His firm or clients may own or trade securities discussed in this column. He can be reached at [email protected].